Rationale for Use of Dopamine Agonists in Parkinson's Disease: Review of Ergot Derivatives

Canadian Journal of Neurological Sciences - United Kingdom
doi 10.1017/s0317167100000056
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

Constrictive Pericarditis and Pleuropulmonary Disease Linked to Ergot Dopamine Agonist Therapy (Cabergoline) for Parkinson's Disease

Mayo Clinic Proceedings
Medicine
1999English

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients With Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists

Internal Medicine
Internal MedicineMedicine
2016English

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine Research
2016English

Dopamine Agonists and Impulse Control Disorders in Parkinson’s Disease

US Neurology
NeuroscienceNeurology
2013English

Dopamine Transporter Imaging Assessment of Parkinson's Disease Progression

2000English

115 Systematic Review of Biomarkers for Disease Progression in Parkinson's Disease

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2012English

Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine

Movement Disorders Clinical Practice
Neurology
2019English

Compulsive Drumming Induced by Dopamine Agonists in Parkinson’s Disease: Another Aspect of Punding

Behavioural Neurology
MedicineNeurologyPhysiological PsychologyNeuropsychology
2013English

Role of Dopamine Β Hydroxylase (DBH) in Parkinson's Disease Patients of Indian Population

Molecular Cytogenetics
BiochemistryMolecular MedicineGeneticsMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy